Condensed Statements of Operations (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Revenue
Product sales	$ 184,179	$ 300,175
Laboratory services	35,241	169,250
Collaborations revenue	252,780	627,780
Total revenue	472,200	1,097,205
Operating expenses
Cost of products sold	115,389	136,107
Cost of services	95,430	97,918
Research and development	1,108,602	952,791
General and administrative	659,392	554,954
Sales and marketing	1,024,029	547,471
Total operating expenses	3,002,842	2,289,241
Operating loss	(2,530,642)	(1,192,036)
Other income (expense)
Interest income	35	37
Interest expense	(96,397)	(8,202)
Change in fair value of derivative financial instruments	31,831
Total other income (expense)	(64,531)	(8,165)
Net loss	(2,595,173)	(1,200,201)
Preferred stock dividends	(171,741)	(110,815)
Net loss available to common stockholders	$ (2,766,914)	$ (1,311,016)
Net loss per common share - basic and diluted	$ (5.61)	$ (3.62)
Weighted average shares outstanding - basic and diluted	493,463	362,537